Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?
News & Analysis: Axsome Therapeutics
One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.
Some traders appear to be taking profits off the table after the stock's jump last week.
The drugmaker received good news from the FDA for one of its pipeline candidates.
Positive results from two pivotal trials helped this stock bounce back from a beatdown in March.
The biotech reported positive news from a late-stage clinical study targeting Alzheimer's disease agitation.
An important clinical trial delivered mixed results.
The development-stage pharmaceutical company gave up a little ground, but important updates are right around the corner.
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Favorable clinical results? Check. Cash from public stock offering? Check.
Axsome's clinical pipeline has scored yet another win.